GPhA’s Next CEO Will Face Political, Regulatory Headwinds
Executive Summary
Ralph Neas will leave the generics association in the fall after a successor is found, as user fee and exclusivity reforms await.
You may also be interested in...
If You Can't Beat 'Em … Hire 'Em? PhRMA Exec Is New GPhA CEO
Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.
GDUFA II Negotiations: Let the Saber-Rattling Begin
The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.
PhRMA Will Pursue Future ‘Cures’ Without Castellani: CEO Retiring Jan. 1
John Castellani will step down at the end of the year as president and CEO of PhRMA after leading the association since September 2010.